This artistic, microscopic visualization illustrates glowing oxaloacetate molecules (gold) interacting with and re-energizing fatigued mitochondria within brain cells to combat the biological factors behind cognitive decline. By restoring cellular energy production and regulating glutamate signaling, this naturally occurring compound is being studied for its potential to clear post-treatment "brain fog" and reduce fatigue in breast cancer survivors.
Image Credit: Scientific Frontline / AI generated
Scientific Frontline: Extended "At a Glance" Summary: Oxaloacetate Supplementation for Cancer-Related Cognitive Impairment
The Core Concept: Oxaloacetate is a naturally occurring molecule involved in cellular energy production that is currently being investigated as a nutritional supplement to alleviate cancer-related cognitive impairment, commonly referred to as "chemo brain" or "brain fog."
Key Distinction/Mechanism: Rather than solely targeting the side effects of chemotherapy, oxaloacetate supplementation aims to mitigate cognitive deficits by regulating glutamate signaling and supporting cellular energy production within the brain—processes that are often disrupted by cancer-associated inflammation and treatments.
Origin/History: The therapeutic potential of oxaloacetate for breast cancer survivors was evaluated in a phase II clinical trial led by UCLA researchers and published in JCO Oncology Advances in October 2026.
Major Frameworks/Components:
- Glutamate Regulation: Modulating neurotransmitter pathways to restore normal cognitive signaling and reduce neuroinflammation.
- Cellular Energy Production: Enhancing metabolic efficiency within brain cells to combat mental fatigue and improve processing speed.
- Neuropsychological Assessment: Utilizing standardized patient-reported questionnaires and cognitive tests to empirically measure improvements in memory, attention, processing speed, and executive function.
Branch of Science: Oncology, Neuroscience, Nutritional Science.
Future Application: The successful implementation of oxaloacetate could lead to standardized, non-pharmacological interventions for managing post-treatment cognitive symptoms, with a randomized, placebo-controlled phase II trial anticipated to open in late 2026 alongside ongoing preclinical murine studies.
Why It Matters: With an estimated 15% to 25% of breast cancer survivors experiencing persistent cognitive difficulties, identifying effective, well-tolerated treatments like oxaloacetate addresses a critical unmet need, significantly improving patients' daily functioning, physical well-being, and overall quality of life.
A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that a nutritional supplement containing oxaloacetate, a molecule naturally found in the body that helps cells produce energy, may help improve cognitive function and reduce the fatigue experienced by some breast cancer survivors following treatment.
The findings, published in JCO Oncology Advances, show that breast cancer survivors with significant cancer-related cognitive impairment, sometimes referred to as “chemo brain” or “brain fog,” experienced improvements in memory, concentration, and other cognitive symptoms after taking oxaloacetate for eight weeks. Participants also reported less fatigue and better physical functioning, while cognitive testing showed improvements in processing speed and executive function, which includes skills such as planning, focusing, and managing tasks.
“Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it,” said Dr. Patricia Ganz, a distinguished professor of medicine at the David Geffen School of Medicine at UCLA and the UCLA Fielding School of Public Health, and first author of the study.
An estimated 15% to 25% of breast cancer survivors may experience persistent cognitive difficulties following breast cancer and its treatment. While cancer-related cognitive impairment has historically been associated with chemotherapy, researchers now recognize that its causes are complex and may involve the cancer itself, chemotherapy, endocrine therapy, inflammation, hormonal changes, and other biological and behavioral factors. With few treatment options available, researchers have been exploring new approaches that target the biological processes that may contribute to these symptoms.
Researchers have been interested in oxaloacetate because inflammation associated with cancer and its treatments may disrupt normal glutamate signaling and cellular energy production in the brain—processes that could contribute to cognitive problems and mental fatigue. Because oxaloacetate plays a role in both glutamate regulation and cellular energy production, the researchers wanted to determine whether taking it as a supplement could help alleviate these symptoms.
To evaluate the supplement’s potential effects, the researchers conducted a phase II clinical trial involving 18 women with early-stage breast cancer who were between one and five years from diagnosis and reported significant cognitive difficulties. The participants had an average age of about 50. Most had previously received chemotherapy, and nearly 90% were receiving endocrine therapy at the time of the study.
Participants took 500 milligrams of oxaloacetate twice daily for eight weeks. Researchers assessed cognitive symptoms before and during treatment using patient-reported questionnaires and standardized neuropsychological tests measuring attention, memory, processing speed, and executive function. They also evaluated fatigue, sleep, anxiety, depression, and physical and mental health, and monitored participants for side effects throughout the study.
Sixteen of the 18 participants completed the eight-week treatment, and all 16 reported significant improvements in their cognitive symptoms. On average, scores on the study’s primary measure of perceived cognitive impairment increased from 29.1 before treatment to 55.5 after eight weeks, moving the group from a range considered impaired to a range considered normal. Improvements were seen after four weeks and generally became greater by the end of treatment.
The researchers also found significant reductions in fatigue, including mental fatigue, and significant improvements in physical functioning. Neuropsychological testing showed improvements in executive function and processing speed, although the researchers noted that these findings are preliminary given the small size of the study.
Oxaloacetate was generally well tolerated. Gastrointestinal symptoms, including indigestion, bloating, constipation, diarrhea, and nausea, were the most common side effects. Two participants discontinued treatment because of gastrointestinal symptoms, and no serious adverse events were reported.
The researchers caution that the study was small and did not include a placebo or comparison group, so further research is needed to determine whether oxaloacetate was responsible for the improvements.
“These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment,” Ganz said.
The team is now preparing for a randomized, placebo-controlled phase II trial in breast cancer survivors with cancer-related cognitive impairment, which is expected to open in late 2026. Preclinical studies involving mice are also underway to better understand how oxaloacetate works and whether a placebo-controlled trial yields similar outcomes, such as reduced fatigue and improved physical function.
Funding: The study was funded in part by the Breast Cancer Research Foundation and the National Cancer Institute.
Published in journal: JCO Oncology Advances
Authors: Patricia A. Ganz, Kathleen Van Dyk, Catherine M. Crespi, Laura Petersen, Mina S. Sedrak, Julienne E. Bower
Source/Credit: University of California, Los Angeles / Health | Denise Heady
Edited by: Scientific Frontline
Reference Number: ongy102126_01
.png)
